GDF3 is a BMP inhibitor that can activate Nodal signaling only at very high doses  by Levine, Ariel J. et al.
Developmental Biology 325 (2009) 43–48
Contents lists available at ScienceDirect
Developmental Biology
j ourna l homepage: www.e lsev ie r.com/deve lopmenta lb io logyGDF3 is a BMP inhibitor that can activate Nodal signaling only at very high doses
Ariel J. Levine, Zachary J. Levine, Ali H. Brivanlou ⁎
Laboratory of Molecular Vertebrate Embryology, The Rockefeller University, New York, NY, USA⁎ Corresponding author. Fax: +212 327 8655.
E-mail address: brvnlou@rockvax.rockefeller.edu (A.
0012-1606/$ – see front matter © 2008 Published by E
doi:10.1016/j.ydbio.2008.09.006a b s t r a c ta r t i c l e i n f oArticle history: Within the TGF-β superfam
Received for publication 6 May 2008
Revised 2 September 2008
Accepted 8 September 2008
Available online 18 September 2008
Keywords:
GDF3
BMP
TGF-β
Embryoily, there are approximately forty ligands divided into two major branches: the
TGF-β/Activin/Nodal ligands and the BMP/GDF ligands. We studied the ligand GDF3 and found that it inhibits
signaling by its co-family members, the BMPs; however, GDF3 has been described by others to have Nodal-
like activity. Here, we show that GDF3 can activate Nodal signaling, but only at very high doses and only upon
mRNA over-expression. In contrast, GDF3 inhibits BMP signaling upon over-expression of GDF3 mRNA, as
recombinant protein, and regardless of its dose. We therefore further characterized the mechanism through
which GDF3 protein acts as a speciﬁc BMP inhibitor and found that the BMP inhibitory activity of GDF3
resides redundantly in the unprocessed, predominant form and in the mature form of the protein. These
results conﬁrm and extend the activity that we described for GDF3 and illuminate the experimental basis for
the different observations of others. We suggest that GDF3 is either a bi-functional TGF-β ligand, or, more
likely, that it is a BMP inhibitor that can artiﬁcially activate Nodal signaling under non-physiological
conditions.
© 2008 Published by Elsevier Inc.IntroductionMany of the key processes of embryonic development and adult
pathophysiology are regulated by the TGF-β superfamily of ligands.
These factors mediate communication between cells to control signal
transduction and transcription in the target cell. In the mammalian
genome, there are approximately forty TGF-β ligands, divided into two
main branches based on homology and function (Lander et al., 2001).
These two branches are roughly distinguished by homology, and
functionally by the major signal transducer that is activated by the
ligands, such that typical TGF-β/Activin/Nodal ligands activate Smad2
and Smad3, while typical BMP/GDF ligands activate Smad1, Smad5,
and Smad8 (reviewed (Shi and Massague, 2003). The high number of
TGF-β ligands could reﬂect signiﬁcant redundancy. However, it is also
likely that there are many levels of subtle variation amongst the
activities of this family of ligands.
There are several atypical TGF-β ligands that have been placed into
one of these two main branches by homology but have different
activities. For instance, GDF1 activates Smad2/3 signaling rather than
Smad1/5/8 (Rankin et al., 2000;Wall et al., 2000), and BMP3 (Daluiski et
al., 2001) and Lefty (Cheng et al., 2004; Meno et al., 1999) act as ligand
inhibitors, blocking classic BMP and Nodal signaling, respectively.
We previously found that GDF3, classiﬁed as a BMP/GDF ligand by
homology, also inhibits BMP signaling through Smad1/5/8, thereby
adding GDF3 to this group of unusual TGF-β ligands (Levine and
Brivanlou, 2006). This conclusion was strengthened by the recent
observation that reduction of endogenous GDF3 levels in humanH. Brivanlou).
lsevier Inc.embryonic stem cells results in enhanced levels of BMP pathway
activation. However, other groups have found that GDF3 is instead a
Nodal-like ligand (Andersson et al., 2007; Chen et al., 2006).
Interestingly, we and others used several common assays, most
prominently over-expression of the mammalian-speciﬁc GDF3 mRNA
in the frog embryo.
To understand the basis for these conﬂicting observations, we
performed studies on GDF3 function using several different sources of
GDF3 throughout a range of doses. We ﬁnd that GDF3 has the unique
feature of acting as a BMP inhibitor throughout its dose range and as a
Nodal-like ligand at high doses. Further, we observed that both the
unprocessed and mature forms of the GDF3 protein inhibit BMP
signaling, but did not observe Nodal-like activity of the GDF3 protein.
This suggests that GDF3 is either a bi-functional ligand, or, more likely,
that GDF3 is a BMP inhibitorwith artiﬁcial Nodal activity at high doses.
GDF3 is now considered to be a classic embryonic stem cell gene
and a required regulator of mammalian embryogenesis. Our ﬁndings
here conﬁrm and extend our previous conclusion that the mechanism
of GDF3 action is through BMP inhibition. We further suggest that
previously observed Nodal-like activity may be an artifact of over-
expression. This discrepancy now requires a reevaluation of the
critical roles of GDF3 in developmental contexts.Results
GDF3 dose determines its function upon over-expression in frog embryos
We ﬁrst conﬁrmed the ﬁndings that our construct for GDF3 acts as
a BMP inhibitor while the constructs for GDF3 used by Chen et al. act
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assay of frog embryos in which endogenous BMP signaling induces
epidermal fates, inhibition of this BMP activity promotes neural fates
(Wilson and Hemmati-Brivanlou, 1995), and activation of the Nodal
pathway induces mesoderm (Smith, 1987; Thomsen et al., 1990) (data
not shown).
To understand the different observations of GDF3 activity, we ﬁrst
analyzed the constructs that each group used to produce GDF3 mRNA.
We had previously studied GDF3 over-expression with a construct
containing only open reading frame (ORF) of GDF3. In contrast, Chen
et al. (2006) and Andersson et al. (2007) used either constructs
containing both the ORF and vector-derived polyA or a chimeric GDF3
mRNA encoding the prepro domain of BMP2 with the mature domain
of GDF3 (Michael Shen, personal communication, (Andersson et al.,
2007), a strategy that has been used frequently in enhancing
processing of TGF-β ligands (Thomsen and Melton, 1993).
We tested the hypothesis that the presence of the polyA signal or
the enhanced processing of GDF3 could promote higher levels of GDF3
mature protein and thus account for the different activities as a doseFig. 1. Dose effects of GDF3 ORF and ORF plus untranslated regions (UTRs). Embryos were i
reading frame (ORF) or the coding region plus UTRs (ORF+UTRs). (A) Top panel: western b
Other panels: RT-PCR showing the effect of GDF3 constructs on cell fate. In lanes 1 and 2, w
as controls for each marker gene. Lane 3 shows uninjected animal caps that express Msx1
GDF3 ORF+UTRs induce BU (mesoderm). ODC is shown as a loading control. (B) Whole em
Caps were uninjected (−), injected with noggin RNA (200 pg) or injected with increasing d
each GDF3 construct are shown. (C) Luciferase assay using an Activin-responsive element (
BRE-Lux experiments, embryos were injected with BRE alone or with BRE and 100 pg of BM
ORF or ORF+UTRs were injected with each reporter.threshold effect. To study the effects of different doses of GDF3, we
injected 1 pg, 10 pg, 100 pg, and 1000 pg of GDF3 ORF mRNAwith and
without endogenous GDF3 UTRs and polyA and analyzed the amount
of GDF3 protein produced. We found that the presence of the UTRs
and polyA allowed production of ten to one hundred timesmore GDF3
protein for each dose of mRNA injected (Fig. 1A). Therefore, injection
of the ORF or the ORF plus UTRs/polyA of GDF3 gives rise to very
different ‘doses’ of GDF3 protein.
We next analyzed whether these different constructs possess
different cell fate inductive activities using the animal cap assay in the
frog embryo. We found that throughout the dose range of the ORF
alone construct (up to 3 ng/embryo), GDF3 acted as a BMP inhibitor,
inducing neural tissue directly (Fig. 1A). However, we found that at
low doses (1, 10 pg), the ORF plus UTRs/polyA construct acted as a
direct neural inducer, the hallmark of BMP inhibition, while at higher
doses (100 pg,1 ng), it acted as a mesoderm inducer, a classic response
to Nodal signaling (Fig. 1A).
In addition to our analysis of cell fate in animal caps, we tested the
ability of GDF3 constructs to induce the typical elongated morphologynjected with increasing doses (1 pg, 10 pg, 100 pg, 1000 pg) of GDF3 RNA for the open
lot with goat anti-GDF3 of embryos injected with increasing doses of GDF3 constructs.
hole embryo mRNA is shown with (1) and without (2) reverse-transcription is shown
(epidermis). Increasing doses of GDF3 induce Sox2 (neural tissue) and high doses of
bryo (stage 17) or animal caps isolated at stage 9 and cultured until sibling stage 17.
oses of GDF3 ORF or ORF+UTRs. Morphology of caps injected with 10, 100, 1000 pg of
ARE-Lux) or a BMP-responsive element (BRE-Lux) driving luciferase reporters. For the
P4 RNA to activate the reporter. Increasing doses (1 pg, 10 pg, 100 pg, 1000 pg) of GDF3
Fig. 3. Recombinant human GDF3 protein (rhGDF3) inhibits BMP activity in animal caps.
Animal caps were isolated from stage 9 embryos and were cultured intact or were
disassociated. The intact caps were treated with increasing doses of rhGDF3 or with
recombinant mouse Nodal (rmNodal) to test for BU (mesoderm) induction. Disas-
sociated caps express Sox2 (neural tissue) but treatmentwith BMP4 alone inducesMsx1
(epidermis). Increasing doses of rhGDF3 protein antagonize BMP4 protein to revert the
cells to a neural state. ODC is shown as a loading control. No RT is a control for genomic
DNA.
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doses of GDF3 ORF alone and GDF3 ORF plus UTRs/polyA. We found
that the ORF alone did not induce elongated dorsal mesoderm and
caps maintained a spherical shape, similar to uninjected caps or caps
injected with noggin, another BMP inhibitor. In contrast, the ORF plus
UTRs/polyA induced dorsal mesoderm elongation at 100 pg and 1 ng
of RNA injection (Fig. 1B).
We conﬁrmed the effects of a dose range of the ORF plus UTRs/
polyA using a luciferase assay. We tested the effects of this construct
on activation of a luciferase gene regulated by a BMP-responsive
element (BRE) and an Activin/nodal responsive element (ARE) (Hata et
al., 2000; Huang et al., 1995). These experiments showed that even
1 pg of the GDF3 coding region plus UTRs/polyA is sufﬁcient for BMP
inhibition, while 100 pg–1 ng is required to activate Nodal-like
signaling (Fig. 1C). To determine whether this type of activity
switching dose response is a common feature of nodal-like ligands,
we tested the luciferase response to a similar dose curve using a
known nodal-like ligand, Xnr1. Xnr1 was not able to inhibit BMP
signaling at low doses (Supplemental Fig. 1).
TGF-β ligands typically exert their activities upon over-expression
of mRNA in the picogram range and can lead to non-speciﬁc activation
of low afﬁnity receptors at high concentrations. Therefore, our results
suggest that function of GDF3 within its physiological dose range is
solely to inhibit BMP signaling.
High doses of GDF3 preserve its BMP inhibitory function and yield
Nodal-like activity
We next sought to determine whether GDF3 switches activity at a
certain dose threshold or acquires Nodal-like activity while retaining
the ability to inhibit BMP signaling. To do this, we analyzed the effects
of over-expressing 1 ng (high dose) of GDF3 ORF plus UTRs/polyAwith
or without α-amanitin, an inhibitor of transcription that prohibits
secondary transcriptional responses. This approach allowed us to
observe the primary effects of GDF3 protein, but not secondary effects
mediated by new transcription. This is important because activation of
Nodal signaling induces dorsal mesoderm which then expresses new
transcripts of BMP inhibitors such as noggin and chordin and thus
includes primary mesoderm induction and secondary BMP inhibition.
We found that a high dose of GDF3 caused inhibition of Smad1/5/8
and direct activation of Smad2/3 in either the absence or presence of
α-amanitin (Fig. 2). Therefore, we demonstrated that GDF3 is a
Smad1/5/8 inhibitor throughout its dose range and that, at very high
doses, this activity is coincident with Smad2/3 activation.
GDF3 unprocessed and mature protein forms both inhibit BMP signaling
The activities observed upon over-expression of mRNA may not
reﬂect true functions of a TGF-β ligand, and protein assays may be
more informative. Therefore, we analyzed the activity of recombinant
human GDF3 protein (rhGDF3) on cell fate in the frog embryo animalFig. 2. Direct effects of GDF3 over-expression in frog embryos. GDF3 was injected with
and without α-amanitin, which blocks protein translation. Embryos were harvested at
stage 9 and analyzed for activation of BMP and Nodal signaling (Psmad1 and Psmad2,
respectively). Stage 6 embryos are shown as a negative control for TGF-β activation,
tubulin is shown as a loading control.cap. It has previously been shown that this manipulation removes
endogenous BMP signals and allows the animal cap cells to adopt a
default neural fate, rather than the epidermal fate that BMPs induce
(Grunz and Tacke, 1989; Wilson and Hemmati-Brivanlou, 1995). We
then challenged these cells with exogenous BMP protein and tested
the ability of rhGDF3 to block the effects of this exogenous BMP
signaling.
We found that, at the doses that we tested, rhGDF3 protein did not
inducemesoderm, althoughmesodermwas induced by the same dose
of recombinant mouse Nodal protein (rmNodal), produced from a
similar source (Fig. 3). While untreated disassociated cells became
neural, rhBMP4 reverted these cells to epidermis. Increasing doses
(0.5, 1 and 4 ng/mL) of rhGDF3 blocked this activity of rhBMP4 (Fig. 3
and data not shown). We also tested 15 ng/mL of rhGDF3 and found
that it had the same effect (data not shown). Therefore, at these
protein doses, GDF3 is a BMP inhibitor and does not act like a Nodal
ligand. We also tested the effects of rhGDF3 protein alone on
disassociated cells and found a synergism in neural induction, with
no mesoderm induction (data not shown).
To determine whether the unusual ‘missing cysteine’ of GDF3
mediated its inhibitory function, we mutated the valine in GDF3 to a
cysteine and tested its function upon BMP induction of the BRE-
luciferase reporter. We found that this ‘V to C’ mutation alone did not
change the ability of GDF3 to block BMP signaling (Fig. 4).
The results above showed that GDF3 mature protein could inhibit
BMP signaling but we also examined whether the GDF3 unprocessed,
‘prepro’ form had this function because GDF3 mainly exists in the
unprocessed form in vivo. We created a cleavage mutant of GDF3 by
mutating the cleavage recognition sequence from amino acids RKRR to
GNVG. This construct produces no mature protein when over-
expressed in frog embryos. Using the luciferase and animal cap cell
fate assays, we found that cleavage mutated GDF3 (CM GDF3) was as
effective as wild-type GDF3 in inhibiting BMP signaling (Fig. 4).
Further, we found that the prepro domain of GDF3 alone is sufﬁcient
for mild BMP inhibition (Fig. 4).
To determine whether GDF3 has redundant mechanisms for
inhibiting BMP signaling, we created a doubly mutated form, having
both the V to C mutation in the mature domain and the cleavage
Fig. 4. The prepro form and domain of GDF3 can inhibit BMP signaling. Luciferase assay
using a BMP-responsive element (BRE) driving expression of a luciferase reporter (BRE-
Lux). Embryos were injected with BMP4 RNA (100 pg/embryo) alone or with 1 ng of
GDF3 constructs for wild-type GDF3 (Wt), a cleavage mutant of GDF3 (CM), or the
prepro domain of GDF3 (prepro). Reporter alone is shown as a baseline control.
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failed to block BMP induction of the luciferase reporter, demonstrating
that redundant regions are responsible for BMP inhibition in the GDF3
protein.
Our results demonstrate that both the unprocessed form of the
GDF3 – the major endogenous form – and the mature form of the
protein – the active form of typical TGF-β ligands, are endowed with
BMP inhibitory function. This redundancy may highlight the impor-
tance of this function. Further, the identiﬁcation of the ‘missing
cysteine’ as a key residue in this activity suggests that other TGF-β
with this feature may also act as inhibitors.
Discussion
Many TGF-β ligands act as morphogens, inducing different cell
fates at different doses (Dosch et al., 1997; Ferguson and Anderson,
1992; Green et al., 1992; Green and Smith, 1990; Wilson et al., 1997).
Importantly, these activities generally rely on graded activation of a
single pathway, and do not involve changing signal transduction
activity. We show here that upon exogenous GDF3 expression in the
frog embryo, GDF3 is a BMP inhibitor, blocking signaling through
Smads1/5/8, but that at high doses, it can also act as a Nodal-like
ligand, stimulating activation of Smads2/3. However, it is unlikely that
this reﬂects a true bi-functionality because GDF3 protein acts solely as
a BMP inhibitor.
Both Levine and Brivanlou (2006) and Chen et al. (2006) performed
principal mechanistic experiments on GDF3 function in frog embryos,
despite the fact that no frog homolog of the mammalian GDF3 has
been described (Chen et al., 2006; Levine and Brivanlou, 2006). While
GDF3 is very similar by overall homology to xVg1, and is considered by
Chen and colleagues to be a Vg1 homolog, several critical character-
istics demonstrate that GDF3 is not the mammalian homolog of Vg1.
First, GDF3 has a deﬁning structural peculiarity, not shared by Vg1, in
that it is missing the fourth of seven canonical cysteines that form the
deﬁning cysteine knot of the TGF-β superfamily. Second, xVg1 is
syntenic with a different GDF ligand, GDF-1. Xenopus tropicalis Vg1
(CAJ82217, peptide Tegg005K01.1) is next to the genes COPE, Ddx49,
then Homer3, the precise arrangement of genes neighboring human
GDF-1 on chromosome 19. Vg1 also shares a high overall homology
with GDF-1 (Lee, 1990), the same complement of canonical cysteines
(Lee, 1990), and a functional similarity (Joseph and Melton, 1998;Thomsen and Melton, 1993; Wall et al., 2000). We therefore do not
consider GDF3 to be related to Vg1. In agreement with Andersson et al.
(2007), we suggest that GDF-1 is the mammalian homolog of Vg1.
Despite the lack of an amphibian homolog of GDF3, there are
several advantages of performing GDF3 over-expression experiments
in frog embryos, including the ability to study in vivo the outcome of
this factor on multiple well deﬁned pathways and the absence of
endogenous GDF3 which allows ectopic expression of a full range of
GDF3 doses with a ‘zero’ baseline. However, a signiﬁcant disadvantage
of this technique is the risk of artifactual results due to exogenous
factor overdose and the observation of non-physiological functions.
Indeed, DNA or RNA mediated over-expression of exogenous have
previously yielded artifactual functional readouts of other TGF-β
ligands in the frog embryo.
To more directly assess the physiological role of GDF3, we studied
the function of the recombinant protein. Our results from experiments
with GDF3 protein show that it is a BMP inhibitor but we did not ﬁnd
any evidence of Nodal-like activity. It is possible that this ﬁnding
reﬂects several technical factors.
First, exogenous recombinant GDF3 protein could be missing
partners with which the protein must be co-synthesized to function.
For instance, in cell culture, GDF3 has been shown to robustly activate
a Nodal-responsive luciferase reporter if it is co-expressed with Nodal
(Andersson et al., 2007).
Second, this could be due to the source of recombinant GDF3
protein, which was bacterial. It is possible that mammalian proteins
produced in E. coli are not properly folded and it is likely that active
GDF3 protein is only a fraction of the total bacterially produced
recombinant protein used in the experiments. For this reason, we also
used bacterially produced recombinant mammalian Nodal protein, as
a control, although the two proteins were not prepared in parallel and
could have different fractions of active protein. Recombinant mouse
Nodal inducedmesoderm at 1 μg/mL, comparable to the range that we
tested for GDF3 (0.25–15 μg/mL).
Third, it could be that we did not test high enough doses of GDF3
protein to reach a threshold of Nodal-like activity. This could not be
done because we could not test one hundred times the active BMP
inhibitory dose of the GDF3 protein, which is a minimum of 0.5 μg/mL.
However, within the range of 0.25–15 μg/mL, already a very signiﬁcant
dose of protein, we found no Nodal-like activity. The company that
produced the GDF3 protein that we used, Peprotech, reports that 0.1–
0.15 μg/mL of protein represents the ED50 for inhibiting alkaline
phosphatase induction in ATDC5 cells, while classic BMP proteins such
as BMP2 and BMP6 induce alkaline phosphatase (data sheet for
product 120–22).
For these reasons, a role for very high levels of GDF3 in promoting
Nodal-like signaling cannot be ruled out, and it is possible that GDF3 is
a bi-functional ligand. Interestingly, Nodal itself has been reported to
inhibit BMP signaling, providing a precedent for this type of dual role
(Yeo andWhitman, 2001). However, it is unclear whether endogenous
Nodal functions through a role in blocking BMP signaling, in addition
to its typical activating role.
The required activities of GDF3 must be analyzed through loss-of-
function, both for examining their effect on BMP and Nodal signaling,
and for incorporating these results into a more comprehensive
understanding of the functions of GDF3 and TGF-β pathways in
their endogenous contexts.
In human embryonic stem cells, Peerani and colleagues showed
that siRNA mediated GDF3 knockdown results in enhanced levels of
Smad1/5/8 activation — the hallmark of BMP pathway signaling
(Peerani et al., 2007). These authors do not demonstrate whether this
regulation is direct, nor whether Nodal signaling is perturbed. It is not
known whether GDF3 also supports stemness through activation of
Nodal-like signaling that has been shown to be required for and to
promote pluripotency in human embryonic stem cells. In human
embryonic stem cells, GDF3 acts to maintain an inner cell mass/
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extra-embryonic tissues, a fate promoted by classic BMPs (Levine and
Brivanlou, 2006; Xu et al., 2002). Together, these results strengthen
the argument that the primary role of endogenous GDF3 is to block
BMP signaling.
GDF3has alsobeen studied in themouseembryo throughaknockout
allele and through a genetrap allele. Both reports describe defects in
anterior visceral endoderm induction or anteriormigration,which likely
represents a requirement for GDF3 in the epiblast during early post-
implantation stages. Nodal signaling has a well-documented role in
anterior visceral endoderm formation (Brennan et al., 2001), and both
papers considered GDF3 activity in this context. However, neither paper
directly assesses the status of Nodal or BMP pathway signaling.
BMP signaling has also been shown to regulate anterior visceral
endoderm establishment, migration, and maintenance. It has been
suggested that BMP4 in the extra-embryonic ectoderm accounts for the
ability of this tissue to inhibit anterior visceral endoderm formation
(Rodriguez et al., 2005). Interestingly, in BMP4-dsRNA treated mouse
embryos, the anterior visceral endoderm either fails to form, remains at
the distal tip of the embryo, or is distal and expanded with ectopic
patches, although this reﬂects reduced levels of BMP4, rather than
enhanced levels of signaling aswould be predicted in the GDF3mutants
(Soares et al., 2005). In the chordin/noggin double mutant that also
would have enhanced BMP signaling, the anterior visceral endoderm is
formed, but not maintained (Bachiller et al., 2000).
Due to the early defects of the GDF3 knockout and genetrap allele,
later roles for GDF3 in the mammalian embryo have not been analyzed.
Based on the localization of GDF3 in the node, anterior axial mesoderm,
and ventral neural tube, it may play a role in neural induction and
patterning. It is possible that GDF3 could inhibit BMP2 and BMP4 to
compensate for the loss of noggin and chordin in the double knockout
and allow posterior neural induction. Another possibility is that GDF3,
as a ligand type of inhibitor, has a distinct role from noggin and chordin,
although they are expressed in similar domains. We have recently
analyzed a genetrap allele of GDF3 and found mostly normal cell fates
throughout the embryo, but a signiﬁcant defect in morphogenesis.
These abnormalities are preceded by expanded activation of BMP
signaling, as analyzed by the distribution of activated Smad1/5/8 (A.J.L.
and A.H.B. manuscript submitted).
The biochemical mechanism through which GDF3 inhibits BMPs is
still unknown. We tested whether the ‘missing’ fourth cysteine in the
GDF3 mature domain endows GDF3 with its unusual activity because
other TGF-β superfamily ligands with this same structural character-
istic are also inhibitors, such as LeftyA and LeftyB. However, we found
that this motif is only required for GDF3 function if the cleavage of the
prepro domain is also mutated, preventing maturation. Therefore,
there seem to be multiple, redundant mechanisms involving both the
prepro domain of GDF3 and the mature domain, which is sufﬁcient to
block BMP signaling.
These data conﬁrm and extend our previous ﬁnding that GDF3 is a
BMP inhibitor and explain the different ﬁndings of Chen, Andersson
and colleagues, who observed that GDF3 can also act like Nodal
(Andersson et al., 2007; Chen et al., 2006).
Materials and methods
Animal cap assays
For intact animal caps, caps of stage 9 embryos were isolated in
0.1X MMR, washed once and transferred immediately to 0.5X MMR
with gentamycin for culture. For animal cap disassociation, caps were
isolated inCMFMmedia (88mMNaCl,1mMKCl, 2.4mMNaHCO3, 5mM
HEPES). Cut caps were transferred to fresh CMFM with 0.5% BSA in an
agarose coated dish for several minutes with the sensorial layer down,
to allow the epithelial layer to peel away; this stepwas aidedwith a hair
knife. Disassociated cap cells were then transferred to 100 μL/well ofCMFM/BSA in pre-coated 96-well plates for protein co-culture for 4 h.
During culture, cells were mixed every 30 min by pipetting up and
down. Cells were then transferred to a pre-BSA-coated Eppendorf tube
containing 0.75XMMR and 10mM Ca2+/Mg2+ and spun at 800 rpm for
2 min to reaggregate the cells. The cell pellet was then cultured until
sibling embryos reached stage 11.5 and harvested for mRNA.
Luciferase assays
All luciferase assays were done in three separate experiments, each
in triplicate; representative individual triplicate experiments are
shown in the results section. In Xenopus embryos, 20 pg of luciferase
DNA construct (BRE-Lux (Hata et al., 2000) or ARE-Lux (Huang et al.,
1995) was injected into the animal region of two cell embryos together
with the indicated RNAs. Pools of four embryoswere harvested at stage
11 in 50 μL of lysis buffer. The error bars indicate standard deviation.
Constructs and reagents
The open reading frame (ORF) of GDF3 and the ORF plus UTRs/
polyA were generously provided by S.J. Lee and R.M. Harland,
respectively. They were both subcloned into the EcoR1/Not1 sites of
pCS2++. For sense RNA, GDF3 was linearized with Not1 and
transcribed with SP6. BMP-4 is in pSP64T and RNA was produced
with EcoR1/SP6. Xnr1 is in pCS2++ and RNAwas produced with Not1/
SP6. The cleavage mutant of GDF3 (coding region alone) in pCS2++
was produced by site-directed mutagenesis with the Stratagene
QuickChange kit using the following primers: CATCCTTCTTCCG-
GAAACGTGGGGGCGGCCATCTCTGTCCCC (sense) and GGGGACAGA-
GATGGCCGCCCCCACGTTTCCGGAAGAAGGATG (anti-sense). The
amino acid coding was converted from RKRR to GNVG. Prepro
GDF3 was cloned by PCR into the EcoR1/Not1 sites of pCS2++. The
primers for prepro cloning were: ATGATGAATTCCACCATGCAGCCT-
TATCAACG (sense) and ATTATGCGGCCGCCCTCCTTTTGCG (anti-
sense). Recombinant human GDF3 protein was purchased from
Peprotech. Recombinant mouse Nodal and human BMP4 proteins
were purchased from R&D Systems. Antibodies for western blots
were goat anti-GDF3 (R&D systems), rabbit anti-Phospho Smads
(1,5,8 or 2,3) (Cell Signaling), and mouse anti-tubulin (Santa Cruz).
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